Novel NLRC4 ‐ALK and EML4‐ALK double fusion mutations in a lung adenocarcinoma patient: A case report

AbstractAnaplastic lymphoma kinase (ALK) rearrangements have been reported in 5% to 6% of non ‐small cell lung cancer (NSCLC) patients. However, the concurrent existence of twoALK fusions within the same patient have rarely previously been reported. Moreover, considering the diversities ofALK mutations, it is necessary to evaluate the response of both double and new types ofALK fusions to ALK ‐tyrosine kinase inhibitors (ALK‐TKIs). Here, we report a case of a 64‐year‐old Chinese woman who was diagnosed with lung adenocarcinoma (ADC) who concurrently harbored two types ofALK‐rearrangements, including an unreportedNLRC4 ‐ALK fusion andEML4 ‐ALK fusion. After surgery, the patient had a progression ‐free survival (PFS) of over 10 months with continuous crizotinib treatment after surgery. Our findings provide a better understanding of ALK‐TKI in patients with two novelALK concomitant fusions.Key pointsA lung adenocarcinoma patient harboring concurrentNLRC4 ‐ALK andEML4 ‐ALK fusion mutations benefited from crizotinib after surgery. Our findings provide important information for future treatment decision ‐making in patients with doubleALK fusions.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research